Biodegradable polymeric nanoformulation based on the antiprotozoal canthin-6-one
Source abstract
Abstract
The efficacy of antiprotozoal agents against intracellular infections is very often limited by an almost negligible access to the cellular level where the pathogens are hidden. As a result, high doses of the chemotherapy agents are needed to be administered, but the great incidence of severe adverse drug effects generally leads to pharmacotherapy failure. To enhance the pharmacological effect of the antiprotozoal and antifungal canthin-6-one, loading into biodegradable poly(octylcyanoacrylate) nanoparticles has been considered. The preparation of canthin-6-one nanoformulation (average size ≈170 nm) has been performed by a single-absorption procedure with high drug loading and little burst release as determined by RP-HPLC. Further characterization of this nanoformulation has been carry out by electrophoretic measurements, analysis of the surface thermodynamics of the nanoparticles, and 1H-NMR analysis. Nanoparticles loaded with canthin-6-one were characterized by a significant hydrophobicity and a great surface electrical charge under physiological conditions. These are two key physicochemical factors determining recognition by the reticuloendothelial system, resulting in a fast intracellular uptake by infected phagocytes. It is expected that this nanoformulation offers potential applications for an efficient canthin-6-one delivery to intracellular infections.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Streptococcal Infections and Treatments · Polymer Surface Interaction Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (25)
Show source-provided references
1. Arias JL, Linares-Molinero F, Gallardo V, Delgado AV (2008) Study of carbonyl iron/poly(butylcyanoacrylate) particles as anticancer drug delivery systems: loading and release properties. Eur J Pharm Sci 33:252–261. doi: 10.1016/j.ejps.2007.12.00510.1016/j.ejps.2007.12.005 ↗
2. Arias JL, Reddy LH, Couvreur P (2009) Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J Drug Target 17:586–598. doi: 10.1080/1061186090310573910.1080/10611860903105739 ↗
3. Arias JL, Martínez-Soler GI, López-Viota M, Ruiz MA (2010) Formulation of chitosan nanoparticles loaded with metronidazole for the treatment of infectious diseases. Lett Drug Des Discov 7:70–78. doi: 10.2174/15701801079022583110.2174/157018010790225831 ↗
4. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P (1996) Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul 13:245–255. doi: 10.3109/0265204960902601310.3109/02652049609026013 ↗
5. Corot C, Robert P, Idee JM, Port M (2006) Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 58:1471–1504. doi: 10.1016/j.addr.2006.09.01310.1016/j.addr.2006.09.013 ↗
6. Couvreur P, Vauthier C (2006) Nanotechnology: intelligent design to treat complex disease. Pharm Res 23:1417–1450. doi: 10.1007/s11095-006-0284-810.1007/s11095-006-0284-8 ↗
7. Cózar-Bernal MJ, Gallardo V, Sáez-Fernández E, Holgado MA, Álvarez-Fuentes J, Fernández-Arévalo M, Arias JL (2010) Role of the electrokinetic properties on the stability of mebendazole suspensions for veterinary applications. Int J Pharm 393:161–166. doi: 10.1016/j.ijpharm.2010.04.031
8. Fattal E, Youssef M, Couvreur P, Andremont A (1989) Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob Agents Chemother 33:1540–154310.1128/AAC.33.9.1540 ↗
9. Ferreira ME, Rojas de Arias A, Torres de Ortiz S, Inchausti A, Nakayama H, Thouvenel C, Hocquemiller R, Fournet A (2002) Leishmanicidal activity of canthin-6-one alkaloids isolated from Zanthoxylum chiloperone var. angustifolium. J Ethnopharmacol 80:199–202. doi: 10.1016/S0378-8741(02)00025-910.1016/S0378-8741(02)00025-9 ↗
10. Ferreira ME, Nakayama H, de Arias AR, Schinini A, de Bilbao NV, Serna E, Lagoutte D, Soriano-Agatón F, Poupon E, Hocquemiller R, Fournet A (2007) Effects of canthin-6-one from Zanthoxylum chiloperone on Trypanosoma cruzi-infected mice. J Ethnopharmacol 109:258–263. doi: 10.1016/j.jep.2006.07.02810.1016/j.jep.2006.07.028 ↗
11. Ferreira ME, Cebrián-Torrejón G, Corrales AS, de Bilbao NV, Rolón M, Gomez CV, Leblanc K, Yaluf G, Schinini A, Torres S, Serna E, Rojas de Arias A, Poupon E, Fournet A (2011) Zanthoxylum chiloperone leaves extract: first sustainable Chagas disease treatment. J Ethnopharmacol 133:986–993. doi: 10.1016/j.jep.2010.11.03210.1016/j.jep.2010.11.032 ↗
12. Holgado MA, Arias JL, Cózar MJ, Alvarez-Fuentes J, Gañán-Calvo AM, Fernández-Arévalo M (2008) Synthesis of lidocaine-loaded PLGA microparticles by flow focusing. Effects on drug loading and release properties. Int J Pharm 358:27–35. doi: 10.1016/j.ijpharm.2008.02.01210.1016/j.ijpharm.2008.02.012 ↗
13. Holgado MA, Cózar-Bernal MJ, Salas S, Arias JL, Álvarez-Fuentes J, Fernández-Arévalo M (2009) Protein-loaded PLGA microparticles engineered by flow focusing: physicochemical characterization and protein detection by reversed-phase HPLC. Int J Pharm 380:147–154. doi: 10.1016/j.ijpharm.2009.07.01710.1016/j.ijpharm.2009.07.017 ↗
14. Imbuluzqueta E, Elizondo E, Gamazo C, Moreno-Calvo E, Veciana J, Ventosa N, Blanco-Prieto MJ (2011) Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections. Acta Biomater 7:1599–1608. doi: 10.1016/j.actbio.2010.11.03110.1016/j.actbio.2010.11.031 ↗
15. Labhasetwar VD, Dorle AK (1990) Nanoparticles: a colloidal drug delivery system for primaquine and metronidazole. J Control Release 12:113–119. doi: 10.1016/0168-3659(90)90087-A10.1016/0168-3659(90)90087-A ↗
16. Lagoutte D, Nicolas V, Poupon E, Fournet A, Hocquemiller R, Libong D, Chaminade P, Loiseau PM (2008) Antifungal canthin-6-one series accumulate in lipid droplets and affect fatty acid metabolism in Saccharomyces cerevisiae. Biomed Pharmacother 62:99–103. doi: 10.1016/j.biopha.2007.07.01410.1016/j.biopha.2007.07.014 ↗
17. Llovet MI, Egea MA, Valero J, Alsina MA, García ML, Chauvet A (1995) Methotrexate-loaded nanoparticles: analysis of drug content and study of the matrix structure. Drug Dev Ind Pharm 21:1761–1771. doi: 10.3109/0363904950906926310.3109/03639049509069263 ↗
18. O’Brien RW, White LR (1978) Electrophoretic mobility of a spherical colloidal particle. J Chem Soc Faraday Trans 2:1607–1626. doi: 10.1039/F2978740160710.1039/f29787401607 ↗
19. Romero EL, Morilla MJ (2010) Nanotechnological approaches against Chagas disease. Adv Drug Deliv Rev 62:576–588. doi: 10.1016/j.addr.2009.11.02510.1016/j.addr.2009.11.025 ↗
20. Soriano-Agatón F, Lagoutte D, Poupon E, Roblot F, Fournet A, Gantier JC, Hocquemiller R (2005) Extraction, hemisynthesis, and synthesis of canthin-6-one analogues. Evaluation of their fungal activities. J Nat Prod 68:1581–1587. doi: 10.1021/np050250z10.1021/np050250z ↗
21. Thouvenel C, Gantier JC, Duret P, Fourneau C, Hocquemiller R, Ferreira ME, Rojas de Arias A, Fournet A (2003) Antifungal compounds from Zanthoxylum chiloperone var. angustifolium. Phytother Res 17:678–680. doi: 10.1002/ptr.113710.1002/ptr.1137 ↗
22. Toti US, Guru BR, Hali M, McPharlin CM, Wykes SM, Panyam J, Whittum-Hudson JA (2011) Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials 32:6606–6613. doi: 10.1016/j.biomaterials.2011.05.03810.1016/j.biomaterials.2011.05.038 ↗
23. Tyagi R, Lala S, Verma AK, Nandy AK, Mahato SB, Maitra A, Basu MK (2005) Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis. J Drug Target 13:161–171. doi: 10.1080/1061186050004673210.1080/10611860500046732 ↗
24. van Oss CJ (2006) Interfacial forces in aqueous media, 2nd edn. CRC Press, Boca Raton10.1201/9781420015768 ↗
25. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P (2003) Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 55:519–548. doi: 10.1016/S0169-409X(03)00041-310.1016/S0169-409X(03)00041-3 ↗